- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00389636
TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
May 5, 2008 updated by: Solsys Medical LLC
Patients will be randomized to receive TheraGauze alone or with Regranex to treat diabetic foot ulcer condition.
The purpose of the study is provide the sponsor with pilot information regarding the ability of TheraGauze to promote wound healing on its own and to examine synergy with Regranex in the treatment of diabetic foot ulcers.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the use of TheraGauzeT (Soluble Systems, LLC) wound dressing, a polymer hydrogel chemically impregnated into a rayon/polyester formed fabric, forming a pliable, conforming solid matrix.
TheraGauze is FDA Class I exempt (regulation #21CFR, product code 5878.4022).
It is hypothesized that this material will be useful for the treatment of full-thickness diabetic ulcers.
It is further hypothesized that this material will enhance the action of Regranex (becaplermin) gel by providing an optimal environment for this growth factor to function.
This study will observe patient outcomes following diabetic foot ulcer treatment with TheraGauze and with or without the use of Regranex.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria: Patients
- who are 18 years old or older;
- who are diagnosed as having insulin-dependent or non-insulin-dependent diabetes mellitus (5.5% <HgBA1C<12%);
- who have foot ulcers extending through the epidermis and dermis but not with exposed tendon or bone;
- who have a diagnosis of chronic diabetic ulcer;
- who have a viable wound bed with granulation tissue as determined by bleeding following debridement;
- who have an ulcer size which is at least 1 cm2 and no greater then 16cm2;
- who have signed an informed consent form.
- who have a wound that has been present for at least 4 weeks at the time of screening.
Exclusion Criteria: Patients
- having ulcers less than 1cm2 or greater than 16cm2 in size;
- having severe arterial disease (ankle brachial index (ABI) less than 0.65);
- having history of radiation therapy to the ulcer site;
- who use corticosteroids >10mg prednisone daily
- who use any immune suppressive, or severely immunocompromised patients;
- who have an ulcer that was of a non-diabetic pathophysiology;
- having vasculitis, severe rheumatoid arthritis, or other collagen vascular disease;
- having malnutrition (defined by albumin <2.5 g/dL);
- having a known allergy or hypersensitivity to the components of either TheraGauze or Regranex;
- having erythema or purulence associated with a severe infection of the wound site;
- having signs and symptoms of cellulitis, osteomyelitis, necrotic or avascular ulcer beds;
- undergoing hemodialysis;
- having uncontrolled diabetes (defined as HgB A1c>12%)
- having deficient blood supply to ulcers (defined as capillary fill time >3 seconds at tips of toes)
- having Charcot's neuroarthropathy as determined by clinical and/or radiographic examination;
- having sickle cell disease;
- having exposed bone, tendon, or fascia;
- who are currently enrolled in a clinical evaluation of another investigational device or drug, or have received and investigational treatment for diabetic foot ulcers in the last 30 days;
- unable to comply with the procedures described in the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1
TheraGauze alone
|
TheraGauze
|
ACTIVE_COMPARATOR: 2
Theragauze + Regranex
|
Regranex + TheraGauze
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Frequency of complete wound healing within 12 weeks
|
Time to complete wound healing within 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
---|
Investigator's or clinician's assessment of wound quality (ulcer duration, baseline area, staging, presence of fibrin or granulation tissue)
|
Patient's assessment (pain, itching)
|
Presence of epithelialization visible on the wound surface
|
Occurrence of infection at the wound site
|
Recurrence of ulcer during the 20 week follow-up period
|
Adverse events (infection, cellulites, seroma, etc.)
|
Excess pain
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Adam Landsman, DPM, PhD, Northwestern University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (ANTICIPATED)
July 1, 2008
Study Completion (ANTICIPATED)
July 1, 2008
Study Registration Dates
First Submitted
October 18, 2006
First Submitted That Met QC Criteria
October 18, 2006
First Posted (ESTIMATE)
October 19, 2006
Study Record Updates
Last Update Posted (ESTIMATE)
May 7, 2008
Last Update Submitted That Met QC Criteria
May 5, 2008
Last Verified
May 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Leg Ulcer
- Skin Ulcer
- Diabetes Complications
- Diabetes Mellitus
- Diabetic Neuropathies
- Foot Diseases
- Diabetic Foot
- Foot Ulcer
- Ulcer
- Physiological Effects of Drugs
- Angiogenesis Modulating Agents
- Growth Substances
- Anticoagulants
- Angiogenesis Inducing Agents
- Becaplermin
Other Study ID Numbers
- SS-0601
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on TheraGauze
-
Eastern Virginia Medical SchoolUnited States Department of Defense; Solsys Medical LLCCompletedFurunculosisUnited States